F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Inclusion Criteria

• Patient is ≥ 18 years old at the time of the drug administration (Patient may be male or female of any race / ethnicity.)
• Patient or patient's legally acceptable representative cognitively provides written informed consent
• Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer
• Patient is scheduled to undergo a conventional bone scan
• Patient is capable of complying with study procedures
• Patient is able to remain still for duration of imaging procedure (about one hour)
• Patient may have had a prior PET or PET/CT scan for staging/restaging.

Exclusion Criteria

• Patient is < 18 years old at the time of the drug administration
• Patient is pregnant or nursing;
• testing on site at the institution (urine or serum ßHCG) within 24 hours prior to the start of investigational product administration
• obtaining surgical history (e.g., tubal ligation or hysterectomy)
• confirming the subject is post menopausal, with a minimum 1 year without menses
• Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
• Patient has known bone metastases
• Patient has previously received [18F]NaF in the last thirty days